TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genscript Biotech ( (HK:1548) ) has provided an update.
Genscript Biotech Corporation announced that its subsidiary, ProBio, received approximately $213.8 million in payments under a licensing agreement with LaNova Medicines Ltd. This agreement grants LaNova an exclusive, worldwide license to develop and commercialize anti-PD-1 single domain antibodies. The payments, which include upfront and milestone payments, as well as sublicense revenue, will enhance ProBio’s cash reserves and strengthen its core competencies. The licensed antibodies demonstrate strong binding and tumor growth inhibition, comparable to Merck’s Keytruda, and have a favorable developability profile for manufacturing.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotechnology industry. The company, along with its subsidiaries, focuses on the development and commercialization of biotechnological products, including anti-PD-1 single domain antibodies, which are used for immunotherapy applications.
YTD Price Performance: 47.36%
Average Trading Volume: 24,869,196
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.43B
Learn more about 1548 stock on TipRanks’ Stock Analysis page.